Literature DB >> 1542298

Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains.

E J Wawrzynczak1, A J Cumber, G D Parnell, P T Jones, G Winter.   

Abstract

The serum half-lives of a wild-type recombinant mouse monoclonal antibody of the IgG2b isotype and a mutant antibody differing from the wild-type antibody by a single amino acid substitution introduced into the CH2 domain, the replacement of Asn 297 by Ala to delete the conserved site of heavy chain glycosylation, were determined in the rat. The biological half-life of the aglycosyl Asn 297-Ala mutant recombinant antibody (4.8 days) was significantly shorter than that of the normally glycosylated wild-type antibody (7.4 days) by enzyme immunoassay. A similar difference between the biological half-lives of 125I-labelled aglycosyl and wild-type antibodies (2.9 and 4.0 days, respectively) was determined by gamma counting. Analysis of serum samples demonstrated that both recombinant antibodies were present in the circulation predominantly as intact monomeric IgG and revealed no differences that could account for the more rapid elimination of the aglycosyl antibody. The results of this investigation indicate that the carbohydrate residues contribute only in part to the survival of IgG in vivo and suggest that the diminished half-life of the aglycosyl antibody is due to increased catabolism in the extravascular tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542298     DOI: 10.1016/0161-5890(92)90102-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  13 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 3.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

4.  Detection of human asialo-alpha(1)-acid glycoprotein using a heterosandwich immunoassay in conjunction with the light addressable potentiometric sensor.

Authors:  K Dill; D W Bearden
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

Review 5.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

6.  Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.

Authors:  W Zhang; P J Lachmann
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

Review 7.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

8.  Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.

Authors:  Wentao Mi; Sylvia Wanjie; Su-Tang Lo; Zhuo Gan; Beatrix Pickl-Herk; Raimund J Ober; E Sally Ward
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Glycosylation profiling of therapeutic antibodies in serum samples using a microfluidic CD platform and MALDI-MS.

Authors:  Tran Thi Thuy; Gunnar Thorsén
Journal:  J Am Soc Mass Spectrom       Date:  2013-04-30       Impact factor: 3.109

10.  Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies.

Authors:  Sheng Yin; Cinthia V Pastuskovas; Leslie A Khawli; John T Stults
Journal:  Pharm Res       Date:  2012-09-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.